Erasca holds $947.8M as FDA fast-tracks RAS glue in metastatic pancreatic cancer
The US regulator's August designation for ERAS-0015 came to light with third-quarter results, as the company pairs a large cash balance with three planned trials in pancreatic and lung cancers.
Erasca ended the third quarter of 2026 with $947.8M in cash, a balance bolstered by a public offering in July that raised about $632.5M. The company reported the figures on 12 November, alongside news of a regulatory milestone for its lead RAS-directed molecular glue, ERAS-0015.
The US Food and Drug Administration granted the drug Fast Track Designation in August for metastatic pancreatic adenocarcinoma. Erasca also said it plans three trials across pancreatic and lung cancers that could potentially support registration.
The material available does not describe the trial designs, patient populations, endpoints or timelines, and it does not break the July offering down further or state how long the cash is expected to last. How far the money stretches across the three studies is therefore not yet clear.
By way of context, Fast Track is an FDA programme for drugs aimed at serious conditions with unmet need. It allows more frequent contact with the agency and can open the way to a rolling submission of an application. It does not guarantee approval and does not lower the bar for showing safety and efficacy.
Why it matters
- Fast Track offers closer FDA dialogue and a possible rolling submission, but the evidentiary standard for approval is unchanged.
- Three planned trials that could support registration across pancreatic and lung cancers mark ERAS-0015 as the centre of Erasca's late-stage ambitions; design details remain undisclosed.
- The $947.8M cash balance after a roughly $632.5M July raise gives Erasca substantial resources, though no runway guidance is available in the material reviewed.
Company's press release (SEC filing): Erasca, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
